|
- 2019
Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trialDOI: 10.1186/s12969-019-0364-z Keywords: Biological therapy, Inflammation, Juvenile idiopathic arthritis, Pharmacokinetics Abstract:
|